Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Paula CramerJulia von TresckowAnna-Maria FinkSandra RobrechtAdam GizaEugen TauschLothar MüllerWolfgang KnaufMatthias ZingerleOthman Al-SawafPetra LangerbeinsKirsten FischerKarl-Anton KreuzerMichael KnebaClemens-Martin WendtnerStephan StilgenbauerBarbara EichhorstMichael HallekPublished in: American journal of hematology (2024)